A. Vitrano

发表

Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.

M. Steinberg, S. Ballas, R. Barone, 2014, Blood cells, molecules & diseases.

Long‐term use of deferiprone significantly enhances left‐ventricular ejection function in thalassemia major patients

P. Cianciulli, L. Cuccia, G. D'Ascola, 2012, American journal of hematology.

Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.

P. Cianciulli, R. Barone, L. Cuccia, 2013, Blood cells, molecules & diseases.

Chelation treatment in sickle‐cell‐anaemia: much ado about nothing?

A. Filosa, A. Maggio, A. Vitrano, 2011, British journal of haematology.

Left Ventricular Diastolic Dysfunction in β-Thalassemia Major with Heart Failure

A. Mancuso, A. Maggio, M. Sacco, 2018, Hemoglobin.

Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience

F. Valenza, A. Maggio, D. Renda, 2010, British journal of haematology.

Primary HBB gene mutation severity and long‐term outcomes in a global cohort of β‐thalassaemia

G. Dardanoni, E. Vichinsky, A. Meloni, 2021, British journal of haematology.

Long‐term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial

G. D’Amico, A. Morabito, C. Gluud, 2009, British journal of haematology.

Reliability of EMA Binding Test in the Diagnosis of Hereditary Spherocytosis in Italian Patients

S. Perrotta, L. Cuccia, A. Maggio, 2010, Acta Haematologica.

Sequential Alternating Deferiprone And Deferoxamine Treatment Compared To Deferiprone Monotherapy: Main Findings And Clinical Follow-Up Of A Large Multicenter Randomized Clinical Trial In -Thalassemia Major Patients

G. D’Amico, A. Morabito, C. Gluud, 2011, Hemoglobin.

Development of a Thalassemia International Prognostic Scoring System (TIPSS).

Filippo Cademartiri, G. Dardanoni, E. Vichinsky, 2022, Blood cells, molecules & diseases.

β-Thalassemia heterozygote state detrimentally affects health expectation.

G. Dardanoni, M. Attanasio, C. Gluud, 2018, European journal of internal medicine.

The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?

L. Cuccia, V. Caruso, A. Filosa, 2017, British journal of haematology.

Real‐life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET

B. Giorgi, G. Abbate, V. Caruso, 2016, European journal of haematology.

Risk of mortality from anemia and iron overload in nontransfusion‐dependent β‐thalassemia

G. Dardanoni, E. Vichinsky, A. Meloni, 2021, American journal of hematology.

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia

G. Dardanoni, E. Vichinsky, A. Meloni, 2021, Haematologica.

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.

M. Cappellini, S. Fucharoen, F. Bonifazi, 2011, Blood cells, molecules & diseases.

Long‐term sequential deferiprone and deferasirox therapy in transfusion‐dependent thalassaemia patients: a prospective clinical trial

A. Pepe, L. Cuccia, V. Caruso, 2019, British journal of haematology.

A complication risk score to evaluate clinical severity of thalassaemia syndromes

G. Dardanoni, E. Vichinsky, A. Meloni, 2020, British journal of haematology.

Random Forest Clustering Identifies Three Subgroups of β-Thalassemia with Distinct Clinical Severity

G. Dardanoni, E. Vichinsky, A. Meloni, 2022, Thalassemia Reports.

Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.

M. Felisi, D. Bonifazi, A. Ceci, 2020, The Lancet. Haematology.

Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.

P. Cianciulli, L. Cuccia, V. Caruso, 2009, Blood cells, molecules & diseases.

Nonsense-mediated decay mechanism is a possible modifying factor of clinical outcome in nonsense cd39 beta thalassemia genotype

M. Attanasio, A. Maggio, A. Giambona, 2012 .

Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5‐year long‐term Italian multicenter randomized clinical trial

L. Pitrolo, A. Maggio, R. Di Maggio, 2015, American journal of hematology.

Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET

D. Fiorino, A. Filosa, L. Pitrolo, 2018, European journal of haematology.

Title: The heterozygote state for β-thalassemia detrimentally affects health outcomes Authors

Gabriella, C. Gluud, S. Scondotto, 2016 .

The heterozygote state for β‐thalassemia detrimentally affects health outcomes

G. Dardanoni, C. Gluud, S. Scondotto, 2017, American journal of hematology.

Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac death.

N. Chattipakorn, A. Phrommintikul, P. Cianciulli, 2013, Blood cells, molecules & diseases.

Mesenchymal Fetal Stem Cells (FMSC) from Amniotic Fluid (AF): Expansion and Phenotypic Characterization

R. Maggio, A. Maggio, M. Sacco, 2015 .

Study on the Efficacy of a JAK Inhibitor Pharmacological Agent As Inducer of Fetal Hemoglobin Production in Cultured Erythroid Precursors from Sickle Cell and Beta-Thalassemia Patients

R. Maggio, A. Maggio, A. Pecoraro, 2015 .

RP1 Dominant p.Ser740* Pathogenic Variant in 20 Knowingly Unrelated Families Affected by Rod–Cone Dystrophy: Potential Founder Effect in Western Sicily

P. Maltese, E. D’Alcamo, T. Avitabile, 2024, Medicina.

Reliability of EMA Binding Test in the Diagnosis of Hereditary Spherocytosis in Italian Patients

S. Perrotta, L. Cuccia, A. Maggio, 2010, Acta Haematologica.